Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods

被引：0
|
作者：
Russell, Meaghan K. [1 ]
Pantazi, Angeliki [1 ]
Lyle, Stephen [2 ]
Tse, Julie Y. [3 ]
机构：
[1] KEW Inc, Lethbridge, AB, Canada
[2] Univ Massachusetts, Worcester, MA 01605 USA
[3] KEW Inc, Tufts Med Ctr, Boston, MA USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
291
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [42] ERBB2 mutation profiling with next-generation sequencing (NGS) in solid tumors.
    Ma, Fei
    Zhang, Min
    Ouyang, Quchang
    Zhao, Jun
    Dong, Xiaorong
    Ai, Xinghao
    Zhu, Bo
    Zhu, Lingjun
    Hu, Wenjing
    Lin, Gen
    Zhang, Xiaotong
    Gu, Yanhong
    Liu, Qiang
    Zhao, Qiong
    Yin, Tiejun
    Chen, Rongrong
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] HER2 copy number variation detected by next-generation sequencing reveals HER2 expression heterogeneity in gastric cancer.
    Zhang, Xiaotian
    Chen, Hui
    Zhao, Xiaochen
    Wang, Jie
    Bai, Yuezong
    CANCER RESEARCH, 2021, 81 (13)
  • [44] HER2 (ERBB2) Immunohistochemistry in Non-Small Cell Lung Cancer: Does Expression Correlate with ERBB2 Mutational Status?
    Cardillo, Anthony
    Kovar, Sierra
    Hicks, David
    Velez, Moises
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1094 - 1095
  • [45] HER2 (ERBB2) Immunohistochemistry in Non-Small Cell Lung Cancer: Does Expression Correlate with ERBB2 Mutational Status?
    Cardillo, Anthony
    Kovar, Sierra
    Hicks, David
    Velez, Moises
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1094 - 1095
  • [46] HER2 Expression in Gastrointestinal Malignancies and Correlation with Next-Generation Sequencing Results
    Karaaslan, S.
    Fernandez, E.
    Velu, P.
    Yemelyanova, A.
    Solomon, J.
    Hissong, E.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S102 - S102
  • [47] PRACTICE ADVANCES ERBB2 (HER2) Alterations in Colorectal Cancer
    Roy-Chowdhuri, Sinchita
    Davies, Kurtis D.
    Ritterhouse, Lauren L.
    Snow, Anthony N.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : 1064 - 1066
  • [48] Resolving the ERBB2 (HER2) Status of Invasive Breast Cancers with Double-Equivocal HER2 Status by Immunohistochemistry and Fluorescence In-situ Hybridization
    Hon, Jane Date
    Zhang, Xinmin
    Edmonston, Tina Bocker
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146 : S96 - S96
  • [49] Detection of ERBB2 Amplification in Breast Carcinoma by Next-Generation Sequencing: A Comparative Study with Immunohistochemistry and Fluorescence in Situ Hybridization
    Ross, D. S.
    Zehir, A.
    Cheng, D. T.
    Ladanyi, M.
    Arcila, M. E.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 760 - 760
  • [50] Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy.
    Zhang, Guo-Chun
    Liao, Ning
    Chen, Bo
    Lin, Jiali
    Lai, Jianguo
    Xiao, Weikai
    Ren, Chong-Yang
    Wen, Ling-Zhu
    Li, XueRui
    Wang, Yulei
    Li, Kai
    Cao, Li
    Jia, Minghan
    Li, Min
    Lizaso, Analyn
    Han Han-Zhang
    Liu, Hao
    Zhang, Lu
    Liu, Jing
    Zhang, Zhou
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345